Keapstone Therapeutics is a dynamic biotech brand focused on developing innovative drugs that target the Nrf2 signaling pathway. With a singular goal in mind, Keapstone aims to tackle two devastating conditions: Parkinson's Disease and Motor Neuron Disease (MND) that collectively impact over 130,000 individuals in the UK. Established in February 2017, Keapstone was co-founded by esteemed collaborators including the University of Sheffield, Parkinson's UK, and renowned scientists Richard Mead and Pamela Shaw from the Sheffield Institute for Translational Neuroscience (SITraN).

As a biotech pioneer, Keapstone possesses exclusive rights to the development of intellectual property linked to a groundbreaking chemical series discovered at Sheffield. By synergizing cutting-edge research from the university, funding and expertise from Parkinson's UK, and the knowledge gleaned from consultants and discovery partners with extensive drug development proficiency, Keapstone is at the forefront of the fight against these debilitating diseases. Stay updated on Keapstone's advancements through their Latest News section, and for any inquiries or collaboration opportunities, feel free to get in touch with them